Antibodies to the FVIII light-chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG

Blood

Volumn 95, Issue 11, 2000, Pages 3435-3441

  Moreau, Alexandre ^b   Lacroix Desmazes, Sébastien ^b   Stieltjes, Natalie ^b   Saenko, Evgueni ^b   Kaveri, Srini V ^b   D'Oiron, Roseline ^b   Sultan, Yvette ^b   Scandella, Dorothea ^b   Kazatchkine, Michel D ^a  

^a HÔPITAL BROUSSAIS   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 ANTIBODY; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN;

AFFINITY CHROMATOGRAPHY; ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; BINDING KINETICS; BLOOD CLOTTING; CLINICAL ARTICLE; CONTROLLED STUDY; HEMOPHILIA A; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MEASUREMENT; PRIORITY JOURNAL;

EID: 0034210622     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.11.3435     Document Type: Article

References (40)

1. De Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Biasi D. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost. 1994;7:544-547.
2. Lusher J, Salzman P. Viral safety and inhibitor development associated with factor VIIIC ultrapurified from plasma in hemophiliacs previously unexposed to factor VIII concentrates. Semin Hematol. 1990;27:1-7.
3. Lusher J, Arkin S, Abilgaard C, Schwartz R. Recombinant FVIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med. 1993;328:453-459.
4. Bray GL, Gomparts ED, Courter S, et al. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood. 1994;83:2428-2435.
5. Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemast. 1981;45:200-203.
6. Algiman M, Dietrich G, Nydegger U, Boieldieu D, Sultan Y, Kazatchkine MD. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci U S A. 1992;89:3795-3799.
7. Gilles JG, Saint-Remy JM. Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest. 1994;94:1496-1505.
8. Gilles JGG, Arnout J, Vermylen J, Saint-Remy JM. Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood. 1993;82:2452-2461.
9. Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitior antibodies by immunoblotting and antibody neutralization. Blood. 1989;74:1618-1626.
10. Scandella D, Kessler C, Esmon P, et al. Epitope specificity and functional characterization of factor VIII inhibitors. In: Aledort LM, ed. Inhibitors to Coagulation Factors. New York, NY: Plenum Press; 1995:47-63.
11. Kasper CK, Aledort LM, Counts RB. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872.
12. Mouthon L, Nobrega A, Nicolas N, et al. Invariance and restriction toward a limited set of self-antigens characterize neonatal IgM antibody repertoires and prevail in autoreactive repertoires of healthy adults. Proc Natl Acad Sci U S A. 1995; 92:3839-3843.
13. Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood. 1993;82:1767-1775.
14. Avrameas S, Guilbert B, Dighiero G. Natural antibodies against tubulin, actin, myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera and monoclonal immunoglobulins from multiple myeloma and Waldenström's macroglobulinemia may express similar antibody specificities. Ann Immunol (Paris). 1981;132C:231-236.
15. Guilbert B, Dighiero G, Avrameas S. Naturally occurring antibodies against nine common antigens in normal human sera. I. Detection, isolation, and characterization. J Immunol. 1982;128: 2779-2787.
16. Vincent C, Revillard J-P. Auto-antibodies specific for β2-microglobulin in normal human serum. Mol Immunol. 1983;20:877-884.
17. Lacroix-Desmazes S, Kaveri SV, Mouthon L, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998;216:117-137.
18. Spalter SH, Kaveri S, Bonnin E, Mani JC, Kazatchkine MD. Normal human serum contains natural antibodies reactive with autologous ABO blood group antigens. Blood. 1999;93:4418-4424.
19. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995;7: 812-818.
20. Hayakawa K, Asano M, Shinton SA, et al. Positive selection of natural autoreactive B cells. Science. 1999;285:113-116.
21. Bendtzen K, Svenson M, Jonsson V, Hippe E. Autoantibodies to cytokines - friends or foes? Immunol Today. 1990;11:167-169.
22. Avrameas S. Natural autoantibodies: from "horror autotoxicus" to "gnothi seauton." Immunol Today. 1991;12:154-159.
23. Adib-Conquy M, Avrameas S, Teminck T. Monoclonal IgM and IgG autoantibodies obtained after polyclonal activation show reactivities similar to those of polyclonal natural autoantibodies. Molec Immunol. 1993;30:119-127.
24. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulins G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol. 1994;1:269-278.
25. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use (IVIg). J Clin Invest. 1996; 97:865-869.
26. Prasad N, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific immunoglobulin G (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol. 1998;161:3781-3790.
27. Vassilev T, Yamamoto M, Aissaoui A, et al. Normal human immunoglobulin suppresses experimental myasthenia gravis in SCID mice. Eur J Immunol. 1999;29:2436-2442.
28. Leyte A, Verbeet MP, Brodniewicz-Proba T, van Mourik JA, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor. Biochem J. 1989;257:679-683.
29. Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem. 1994; 269:11,601-11,605.
30. Vlot AJ, Koppelman SJ, Meijers JCM, et al. Kinetics of factor VIII-von Willebrand factor association. Blood. 1996;87:1809-1816.
31. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240-246.
32. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984;2(8406):765-768.
33. Rossi F, Sultan Y, Kazatchkine MD. Anti-idiotypes against autoantibodies and alloantibodies to factor VIII:C (anti-haemophilic factor) are present in therapeutic polyspecific normal immunoglobulins. Clin Exp Immunol. 1988;74:311-316.
34. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing anti-idiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest. 1996;97:1382-1388.
35. Green D, Kwaan HC. An acquired factor VIII inhibitor responsive to high-dose gammagloblin. Thromb Haemost. 1987;58:1005-1007.
36. Zimmermann R, Kommerell B, Harenberg J, Eich W, Rother K, Schimpf KL. Intravenous IgG for patients with spontaneous inhibitor to factor VIII. Lancet. 1985;1(8423):273-274.
37. Kazatchkine MD, Dietrich G, Hurez V, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (IVIg). Immunol Rev 1994;139:79-107.
38. Cosenza H, Kohler H. Specific inhibition of plaque formation to phosphorylcholine by antibody against antibody. Science. 1972;176: 1027-1029.
39. Dietrich G, Varela FJ, Hurez V, Bouanani M, Kazatchkine MD. Selection of the expressed B cell repertoire by infusion of normal immunoglobulin G in a patient with autoimmune thyroiditis. Eur J Immunol. 1993;23:2945-2950.
40. Kazatchkine MD, Sultan Y, Burton-Kee EJ, Mowbray JF. Circulating immune complexes containing anti-FVIII antibodies in multitransfused patients with haemophilia A. Clin Exp Immunol. 1980;39:315-320.